102 related articles for article (PubMed ID: 9450811)
21. [Study on the sensitization of acute myeloid leukemia cell to daunorubicin by recombinant human interleukin-3].
Wang J; Wang Q; Chen X
Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):30-2. PubMed ID: 11498841
[TBL] [Abstract][Full Text] [Related]
22. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
23. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.
Swerts K; de Moerloose B; Dhooge C; Noens L; Laureys G; Benoit Y; Philippé J
Leuk Lymphoma; 2004 Nov; 45(11):2221-8. PubMed ID: 15512810
[TBL] [Abstract][Full Text] [Related]
25. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O
Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923
[TBL] [Abstract][Full Text] [Related]
26. Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.
Kim DH; Lee NY; Kim JG; Sohn SK; Won DI; Suh JS; Lee GS; Chae SC; Lee KB
Leuk Lymphoma; 2005 Jan; 46(1):63-70. PubMed ID: 15621782
[TBL] [Abstract][Full Text] [Related]
27. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia.
Lagadinou ED; Ziros PG; Tsopra OA; Dimas K; Kokkinou D; Thanopoulou E; Karakantza M; Pantazis P; Spyridonidis A; Zoumbos NC
Leukemia; 2008 Oct; 22(10):1899-908. PubMed ID: 18650843
[TBL] [Abstract][Full Text] [Related]
28. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
[TBL] [Abstract][Full Text] [Related]
30. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
Côme MG; Skladanowski A; Larsen AK; Laurent G
Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
[TBL] [Abstract][Full Text] [Related]
31. Flow cytometric monitoring of fluorescent drug retention and efflux.
Krishan A; Hamelik RM
Methods Mol Med; 2005; 111():149-66. PubMed ID: 15911978
[TBL] [Abstract][Full Text] [Related]
32. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.
Sonneveld P; Nooter K
Br J Haematol; 1990 Jun; 75(2):208-11. PubMed ID: 2372507
[TBL] [Abstract][Full Text] [Related]
33. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
34. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
35. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Lancet JE; Baer MR; Duran GE; List AF; Fielding R; Marcelletti JF; Multani PS; Sikic BI
Leuk Res; 2009 Aug; 33(8):1055-61. PubMed ID: 19108889
[TBL] [Abstract][Full Text] [Related]
36. In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells.
Dorlhiac-Llacer PE; Marquezini MV; Toffoletto O; Carneiro RC; Maranhão RC; Chamone DA
Braz J Med Biol Res; 2001 Oct; 34(10):1257-63. PubMed ID: 11593299
[TBL] [Abstract][Full Text] [Related]
37. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia.
De Toni F; Racaud-Sultan C; Chicanne G; Mas VM; Cariven C; Mesange F; Salles JP; Demur C; Allouche M; Payrastre B; Manenti S; Ysebaert L
Oncogene; 2006 May; 25(22):3113-22. PubMed ID: 16407823
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
39. Drug sensitivity assay for leukaemic cells by flow cytometry.
Gupta M; Naik S; Pandey CM; Dabadghao S
Indian J Med Res; 2002 Jun; 115():260-4. PubMed ID: 12440199
[TBL] [Abstract][Full Text] [Related]
40. [Detection of multidrug resistance in patients with leukemia by using flow cytometry and RNA in situ hybridization].
Li S; Wang C; Yao C
Zhonghua Nei Ke Za Zhi; 1996 Sep; 35(9):591-4. PubMed ID: 9592351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
